Cargando…

Phosphoinositide 3-kinase inhibitors are effective therapeutic drugs for the treatment of hepatocellular carcinoma?

Detalles Bibliográficos
Autores principales:	Park, Jeong Su, Bae, Soo Han
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association for the Study of the Liver 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641560/ https://www.ncbi.nlm.nih.gov/pubmed/32937686 http://dx.doi.org/10.3350/cmh.2020.0143

Ejemplares similares

Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)
por: Huang, Xueqin, et al.
Publicado: (2023)

Phosphoinositide 3-Kinase Inhibitor-Induced Hyperglycemia
por: Shey, Susan, et al.
Publicado: (2021)

The Novel Therapeutic Effect of Phosphoinositide 3-Kinase-γ Inhibitor AS605240 in Autoimmune Diabetes
por: Azzi, Jamil, et al.
Publicado: (2012)

Drug-eluting beads in hepatocellular carcinoma
por: Abe, Hiroyuki, et al.
Publicado: (2017)

Hepatocellular carcinoma and immunotherapy: Beyond immune checkpoint inhibitors
por: Abushukair, Hassan Mohammed, et al.
Publicado: (2022)

Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma
por: Jiang, Lei, et al.
Publicado: (2023)

Therapeutic Potential of Autophagy in Glioblastoma Treatment With Phosphoinositide 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin Signaling Pathway Inhibitors
por: Xia, Qin, et al.
Publicado: (2020)

Megestrol treatment in patients with hepatocellular carcinoma
por: Farinati, F, et al.
Publicado: (2001)

Erratum: Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma
por: Frontiers Production Office,
Publicado: (2023)

Multikinase inhibitor-based immunotherapy doublet for advanced hepatocellular carcinoma: its efficacy still needs to be determined
por: Li, Heming, et al.
Publicado: (2023)

Letter regarding “Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab”
por: Bae, Sun Hyun, et al.
Publicado: (2023)

Two distinct stem cell‐like subtypes of hepatocellular carcinoma with clinical significance and their therapeutic potentials
por: Lee, Sung Hwan, et al.
Publicado: (2022)

Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases
por: Apsel, Beth, et al.
Publicado: (2008)

Xihuang pills induce apoptosis in hepatocellular carcinoma by suppressing phosphoinositide 3-kinase/protein kinase-B/mechanistic target of rapamycin pathway
por: Teng, Yong-Jie, et al.
Publicado: (2022)

Identification of Novel Piperazinylquinoxaline Derivatives as Potent Phosphoinositide 3-Kinase (PI3K) Inhibitors
por: Wu, Peng, et al.
Publicado: (2012)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Casticin inhibits nasopharyngeal carcinoma growth by targeting phosphoinositide 3-kinase
por: Liu, Jingxian, et al.
Publicado: (2019)

The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications
por: Arcaro, Alexandre, et al.
Publicado: (2007)

Inositol Polyphosphate-Based Compounds as Inhibitors of Phosphoinositide 3-Kinase-Dependent Signaling
por: Maffucci, Tania, et al.
Publicado: (2020)

Compartmentalisation of EGFR signalling might potentiate the optimal use of EGFR tyrosine kinase inhibitors in cancer therapeutics
por: Karamouzis, M V, et al.
Publicado: (2007)

Implications of pseudogenes for the prognosis of hepatocellular carcinoma
por: Liu, Zaoqu, et al.
Publicado: (2023)

A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer
por: Shaurova, Tatiana, et al.
Publicado: (2023)

Effects of Novel Isoform-Selective Phosphoinositide 3-Kinase Inhibitors on Natural Killer Cell Function
por: Yea, Sung Su, et al.
Publicado: (2014)

Radical resection and reconstruction of the sternum for metastasis of hepatocellular carcinoma
por: Yoon, Young Chul, et al.
Publicado: (2020)

Phosphoinositide 3-kinase-delta could be a biomarker for eosinophilic nasal polyps
por: Kim, Jong Seung, et al.
Publicado: (2018)

Long‐term antibiotic use and risk of hepatocellular carcinoma later in life: a nationwide cohort study of 9.8 million participants
por: Jeong, Seogsong, et al.
Publicado: (2023)

Phosphoinositide 3′-Kinase γ Facilitates Polyomavirus Infection
por: Clark, Paul, et al.
Publicado: (2020)

PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma
por: Yang, Xiao-Dong, et al.
Publicado: (2021)

Octreotide and hepatocellular carcinoma
por: Farinati, F, et al.
Publicado: (2007)

Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 Has a Therapeutic Potential and Sensitizes Cisplatin in Nasopharyngeal Carcinoma
por: Yang, Fen, et al.
Publicado: (2013)

Long-Term Regression after Discontinuation of Regorafenib Administered for Sorafenib-Refractory Hepatocellular Carcinoma
por: Bae, Heewon, et al.
Publicado: (2023)

TIPE-2 suppresses growth and aggressiveness of hepatocellular carcinoma cells through downregulation of the phosphoinositide 3-kinase/AKT signaling pathway
por: Wang, Lin, et al.
Publicado: (2018)

Phosphoinositide-3-Kinase Is the Primary Mediator of Phosphoinositide-Dependent Inhibition in Mammalian Olfactory Receptor Neurons
por: Ukhanov, Kirill, et al.
Publicado: (2016)

Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas
por: Janus, Joanna M., et al.
Publicado: (2017)

Correction to: Casticin inhibits nasopharyngeal carcinoma growth by targeting phosphoinositide 3-kinase
por: Liu, Jingxian, et al.
Publicado: (2021)

Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics
por: Murthy, Divya, et al.
Publicado: (2018)

Therapeutic drug monitoring in inflammatory bowel disease treatments
por: Wang, Meng-Yao, et al.
Publicado: (2022)

Initiation of human astrovirus type 1 infection was blocked by inhibitors of phosphoinositide 3-kinase
por: Tange, Shoichiro, et al.
Publicado: (2013)

Effects of a Phosphoinositide-3-Kinase Inhibitor on Anaplastic Thyroid Cancer Stem Cells
por: Bozorg-Ghalati, Farzaneh, et al.
Publicado: (2017)

Sodium-Glucose Cotransporter-2 Inhibitors for Hyperglycemia in Phosphoinositide 3-kinase Pathway Inhibition
por: Weintraub, Michael A, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h2f0lfnt7nilh4v5u8vg3gum94